A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Padagis LLC; Paddock Laboratories, Inc.
• Treatments: Flavoxate

Criteria

Inclusion Criteria:

• Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening

Exclusion Criteria:

• Positive test results for HIV or Hepatitis B or C

• History of allergy or sensitivity to Flavoxate hydrochloride or related drugs